Highlights for March 2017
- Sun Pharma's arm to acquire Canadian drug firm Thallion
- Lupin in talks with Sanofi's Zentiva to buy inhaler brand
- Sanofi pays €120M to buy into AstraZeneca RSV program
- Marathon Pharma sells Emflaza drug to PTC Therapeutics in a deal potentially worth more than $190 million.
- Torrent Pharmaceuticals to acquire some products of Novartis
- OncBioMune Announces Term Sheet to Acquire Norepinefrine from Teva Pharmaceuticals in Mexico
- Glenmark Pharmaceuticals and Evestra, Inc. Announce Partnership Agreement for Generic NuvaRing®-
- Jubilant Life Sciences explores acquisition of US-based pharma biz
- Dr. Reddy’s partners with Integra LifeSciences to market and distribute DuraGen products in India
- Tessa Therapeutics buys Euchloe Bio for its suite of checkpoint inhibitors
- BioLineRx buys Agalimmune to expand cancer pipeline
- Piramal completes acquisition of Mallinckrodt LLC's pain drug portfolio
For more such news and updates, please join our Group "Global Life Science Business Partnering" on LinkedIn.
Updates at Aagami:
- New client win for Aagami - Netherlands HQ'd company with First-in-class phase-3-ready drug candidate for Post Operative Firbrosis (POF)
- Aagami CEO attends a fruitful BIO Asia in Japan 14-15 March
- Aagami CEO completes a successful business trip to Japan and Korea (March 10-29)Aagami CEO to visit San Francisco, San Diego and Los Angeles, along with client CEO for high level strategic meetings for co-development partnerships (March 27 to April 7)